Leonid Timashev
Stock Analyst at RBC Capital
(4.16)
# 755
Out of 5,182 analysts
165
Total ratings
54.42%
Success rate
12.29%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Outperform | $140 → $162 | $150.55 | +7.61% | 3 | Apr 14, 2026 | |
| INSM Insmed | Maintains: Outperform | $212 → $216 | $144.15 | +49.84% | 9 | Apr 14, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $49 → $53 | $34.27 | +54.65% | 6 | Apr 14, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Sector Perform | $11 → $7 | $5.32 | +31.58% | 3 | Mar 18, 2026 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $18 → $14 | $4.32 | +224.07% | 2 | Mar 17, 2026 | |
| LEGN Legend Biotech | Maintains: Outperform | $66 → $62 | $21.38 | +189.99% | 16 | Mar 11, 2026 | |
| DSGN Design Therapeutics | Maintains: Outperform | $13 → $14 | $13.45 | +4.09% | 11 | Mar 10, 2026 | |
| NUVB Nuvation Bio | Maintains: Outperform | $12 → $13 | $5.00 | +160.00% | 5 | Mar 3, 2026 | |
| BHVN Biohaven | Maintains: Outperform | $22 → $23 | $10.57 | +117.60% | 15 | Mar 3, 2026 | |
| EXEL Exelixis | Maintains: Sector Perform | $46 → $43 | $44.89 | -4.21% | 4 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $417 → $425 | $328.07 | +29.55% | 6 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $45 | $34.51 | +30.40% | 6 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $191 → $195 | $201.96 | -3.45% | 4 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $219 → $222 | $186.98 | +18.73% | 16 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $95 → $101 | $65.74 | +53.64% | 7 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $6.72 | +227.62% | 6 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $61 → $73 | $69.07 | +5.69% | 3 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $34.63 | +35.72% | 9 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $13 | $7.42 | +75.20% | 3 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $1.74 | +187.36% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $1.03 | +288.35% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $50 | $34.69 | +44.13% | 15 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $19 | $13.10 | +45.04% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $6.71 | +93.74% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $4.40 | +13.64% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $0.91 | +229.53% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $97.57 | -28.26% | 1 | Jan 23, 2025 |
Revolution Medicines
Apr 14, 2026
Maintains: Outperform
Price Target: $140 → $162
Current: $150.55
Upside: +7.61%
Insmed
Apr 14, 2026
Maintains: Outperform
Price Target: $212 → $216
Current: $144.15
Upside: +49.84%
IDEAYA Biosciences
Apr 14, 2026
Maintains: Outperform
Price Target: $49 → $53
Current: $34.27
Upside: +54.65%
Bicycle Therapeutics
Mar 18, 2026
Maintains: Sector Perform
Price Target: $11 → $7
Current: $5.32
Upside: +31.58%
Perspective Therapeutics
Mar 17, 2026
Maintains: Outperform
Price Target: $18 → $14
Current: $4.32
Upside: +224.07%
Legend Biotech
Mar 11, 2026
Maintains: Outperform
Price Target: $66 → $62
Current: $21.38
Upside: +189.99%
Design Therapeutics
Mar 10, 2026
Maintains: Outperform
Price Target: $13 → $14
Current: $13.45
Upside: +4.09%
Nuvation Bio
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $13
Current: $5.00
Upside: +160.00%
Biohaven
Mar 3, 2026
Maintains: Outperform
Price Target: $22 → $23
Current: $10.57
Upside: +117.60%
Exelixis
Mar 2, 2026
Maintains: Sector Perform
Price Target: $46 → $43
Current: $44.89
Upside: -4.21%
Feb 27, 2026
Maintains: Outperform
Price Target: $417 → $425
Current: $328.07
Upside: +29.55%
Feb 26, 2026
Maintains: Outperform
Price Target: $47 → $45
Current: $34.51
Upside: +30.40%
Feb 25, 2026
Maintains: Outperform
Price Target: $191 → $195
Current: $201.96
Upside: -3.45%
Feb 24, 2026
Maintains: Outperform
Price Target: $219 → $222
Current: $186.98
Upside: +18.73%
Feb 20, 2026
Maintains: Outperform
Price Target: $95 → $101
Current: $65.74
Upside: +53.64%
Feb 18, 2026
Maintains: Outperform
Price Target: $21 → $22
Current: $6.72
Upside: +227.62%
Jan 21, 2026
Maintains: Outperform
Price Target: $61 → $73
Current: $69.07
Upside: +5.69%
Jan 21, 2026
Maintains: Outperform
Price Target: $44 → $47
Current: $34.63
Upside: +35.72%
Jan 21, 2026
Maintains: Outperform
Price Target: $22 → $13
Current: $7.42
Upside: +75.20%
Dec 19, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $1.74
Upside: +187.36%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.03
Upside: +288.35%
Nov 7, 2025
Maintains: Outperform
Price Target: $49 → $50
Current: $34.69
Upside: +44.13%
Nov 6, 2025
Maintains: Outperform
Price Target: $18 → $19
Current: $13.10
Upside: +45.04%
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $6.71
Upside: +93.74%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $4.40
Upside: +13.64%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $0.91
Upside: +229.53%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $97.57
Upside: -28.26%